AtriCure (NASDAQ:ATRC) Given Market Outperform Rating at JMP Securities

JMP Securities restated their market outperform rating on shares of AtriCure (NASDAQ:ATRC) in a research note issued to investors on Monday,Benzinga reports. JMP Securities currently has a $60.00 target price on the medical device company’s stock.

Other equities research analysts have also issued research reports about the stock. Needham & Company LLC boosted their price target on shares of AtriCure from $40.00 to $51.00 and gave the stock a “buy” rating in a report on Wednesday, January 22nd. Canaccord Genuity Group boosted their target price on shares of AtriCure from $53.00 to $61.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $40.00 price target on shares of AtriCure in a research note on Tuesday, December 17th. UBS Group boosted their price objective on AtriCure from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Finally, Oppenheimer increased their target price on AtriCure from $32.00 to $36.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $45.22.

AtriCure Stock Up 2.5 %

ATRC stock opened at $42.01 on Monday. AtriCure has a one year low of $18.94 and a one year high of $43.11. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.59 and a current ratio of 3.62. The firm’s fifty day moving average is $35.19 and its 200 day moving average is $30.83. The firm has a market cap of $2.05 billion, a PE ratio of -50.61 and a beta of 1.46.

Institutional Investors Weigh In On AtriCure

Large investors have recently made changes to their positions in the stock. Arcadia Investment Management Corp MI acquired a new position in AtriCure during the third quarter worth $28,000. Heck Capital Advisors LLC purchased a new position in shares of AtriCure during the 4th quarter worth $60,000. Venturi Wealth Management LLC raised its holdings in shares of AtriCure by 1,337.6% during the 4th quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock worth $69,000 after acquiring an additional 2,100 shares during the period. KBC Group NV boosted its position in shares of AtriCure by 65.3% during the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock valued at $72,000 after acquiring an additional 932 shares during the last quarter. Finally, R Squared Ltd purchased a new stake in shares of AtriCure in the fourth quarter valued at about $89,000. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.